Quinacainol (RP 54272) is a new antiarrhythmic compound with class I antiarrhythmic effects in rats.

Quinacainol blocked sodium currents in a concentration-dependent manner and with a potency similar to that of quinidine (mean (+/-SEM) EC50 50+/-12 vs 95+/-25 micromol/L for quinidine and quinacainol, respectively). Quinacainol, a quinidine analog, blocks sodium currents in cardiac myocytes with little effect on I (to) or iKsus potassium currents, which suggests that quinacainol may be exerting class 1c anti-arrhythmic actions.[1]

Evaluation of antiarrhythmic effects using Quinacainol in conscious rats with LAD coronary artery occlusion. Antiarrhythmic actions occurred with 2.0 and 4.0 mg/kg, whereas 8.0 mg/kg was pro-arrhythmic. At doses of 0.5 mg/kg and above, quinacainol increased threshold currents for capture and for ventricular fibrillation. Doses of 2.0 mg/kg and above increased ventricular refractoriness. From 1.0 to 8.0 mg/kg, quinacainol reduced dV/dtmax of phase 0 of epicardial action potentials but only 8.0 mg/kg increased action potential duration. The Q-T interval was also increased with the highest dose. Quinacainol dose-relatedly increased P-R interval whereas QRS did not change. Thus the Class I electrophysiological properties of quinacainol over the dose range tested did not fit accurately into a single subclass of the various subclasses of Class I. However, the Class Ic actions seen with 2.0 and 4.0 mg/kg were associated with antiarrhythmic actions.[2]

DMSO: 50 mg/mL (153.15 mM), Sonication is recommended.